Aroa Biosurgery’s Myriad Shows Promise in Cost-Effective Limb Reconstruction

Aroa Biosurgery Ltd (AU:ARX) has released an update.

Aroa Biosurgery Limited’s recent study highlights the efficacy and cost savings of its Myriad products in lower limb reconstruction. The study demonstrated successful tissue coverage with just one application, achieving up to 195% cost savings compared to other dermal substitutes. This positions Aroa Biosurgery strongly in a significant market opportunity for lower limb procedures.

For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.